New strategy: removing tumors one by one after chemo for stomach and pancreatic cancers

NCT ID NCT07282912

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial chemotherapy. About 54 participants will be randomly assigned to either standard care or standard care plus these sequential tumor-removal procedures. The main goal is to see if this approach delays cancer progression or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sequential cytoreductive intervention (a series of procedures to remove cancerous tumors one after another)
What this could lead to
If successful, this approach could extend the time patients with advanced foregut cancer live without their disease getting worse, potentially pointing to a new treatment strategy.
What could go wrong
This is a small, early-phase trial with only 54 participants, so results may not apply to everyone. The procedures carry risks like infection or complications, and the benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMPULLARY ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Smilow Cancer Center

    RECRUITING

    New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.